FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

OMB APPROVAL

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Whale Gary			2. Date of Requiring (Month/D 03/20/2	Statement ay/Year)	3. Issuer Name and Ticker or Trading Symbol Zura Bio Ltd [ZURA]							
(Last) 4225 EXEC SUITE 600	(First) UTIVE SQUA	(Middle)				4. Relationship of Reporting Issuer (Check all applicable) Director X Officer (give title below)		wner	(Oricon Applicable Line)			
(Street) LA JOLLA (City)		92037 (Zip)	_		EVP and		below)	X		Form filed by One Reporting Person Form filed by More than One Reporting Person		
Table I - Non-Derivative Securities Beneficially Owned												
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)		r. Form: D (D) or In			4. Nature of Indirect Beneficial Ownership (Instr. 5)		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
Ex			2. Date Exercisable and Expiration Date Month/Day/Year)		3. Title and Amount of Sec Underlying Derivative Sec (Instr. 4)			4. Conversion or Exercise Price of		5. Ownership Form:	6. Nature of Indirect Beneficial	
			Date Exercisable				Amount or Number of Shares	Derivativ Security	re	Direct (D) or Indirect (I) (Instr. 5)	Ownership (Instr. 5)	
Employee Sh Buy)	nare Option (R	Light to	(1)	03/15/2033	Clas	s A Ordinary Shares	158,882(2)	58,882 ⁽²⁾ 1.2		D		

Explanation of Responses:

- 1. The Reporting Person was granted the option on March 15, 2023. 25% of the shares underlying the option vest one year after the grant date, then the remaining shares vest in monthly installments of 2.083% thereafter starting on the last day of the following full month until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- 2. In connection with the closing of the business combination between the Issuer and Zura Bio Limited, a company incorporated under the laws of England and Wales ("Zura"), among other things, each ordinary share of Zura was exchanged pursuant to the terms of the Business Combination Agreement (including the corporate restructuring of Zura contemplated therein) into Class A Ordinary Shares of the Issuer (the exchange ratio used for such exchange is hereinafter referred to as the "Exchange Ratio"). In addition, each outstanding Zura equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Zura equity awards.

<u>/s/ Gary Whale</u> <u>03/21/2023</u>

** Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

 $Note: File \ three \ copies \ of \ this \ Form, \ one \ of \ which \ must \ be \ manually \ signed. \ If \ space \ is \ insufficient, \ see \ Instruction \ 6 \ for \ procedure.$

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.